TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02528760
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin to be given 70mg iv 12 hourly.
Study: NCT00740389
Drug: TMC125
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02984111
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04258163
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000-1250 mg/m 2 PO twice daily days 1-14, cycled every 28 days
Study: NCT04258163
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m 2 IV day 1, cycled every 28 days
Study: NCT03633890
Drug: DaZhu Rhodiola Rosea Capsule
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, 4 capsules, 3 times a day, for 8 weeks
Study: NCT03633890
Drug: DaZhu Rhodiola Rosea Simulation Capsule
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, 4 capsules, 3 times a day, for 8 weeks
Study: NCT03654196
Drug: HL301(Experimental)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total 7 days of treatment and The daily dose is as follows \[Morning: HL301 1Tab + Placebo of Umkamin 1Tab\] \[Noon: Placebo of Umkamin 1Tab\] \[Evening: HL301 1Tab + Placebo of Umkamin 1Tab\]
Study: NCT04814745
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol administration
Study: NCT03155048
Drug: Estradiol transdermal patch
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal estradiol group for endometrial preparation
Study: NCT00002725
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03830125
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to BBT-877, oral capsule
Study: NCT00714103
Drug: 8-Chloro-Adenosine
Normalized name: 2-chloro-2'-deoxy-adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg/m\^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).
Study: NCT03092453
Drug: Cyclophosphamide 300mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered prior to subject's first DC dose
Study: NCT01999179
Drug: Heparin, Low-Molecular-Weight, or direct oral anticoagulants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
Study: NCT02927509
Drug: TNF alpha blockers
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002554
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002554
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04505033
Drug: HB0017
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB0017 at 100 mg/mL (1 mL/vial) in 2 mL glass vial with a rubber stopper. HB0017 will be administered in the abdominal area by a subcutaneous injection in the mornings. A maximum volume of 1 mL is injected per site.
Study: NCT04505033
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching injection solution containing a specific volume of normal saline (0.9%, Sodium Chloride Injection USP) and no active substance will be prepared for the subjects who will be assigned to placebo according to the dose schedule.
Study: NCT01452451
Drug: HM11260C
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3
Study: NCT01452451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3
Study: NCT00419770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04500470
Drug: Ketoprofen + INH
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure
Study: NCT04500470
Drug: Ketoprofen + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table placebo by the patient 12 hours before the procedure
Study: NCT02033109
Drug: PC-1005
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal use
Study: NCT02033109
Drug: HEC gel
Normalized name: ALCOHOL 73 L in 100 L TOPICAL GEL [Grand Valley Reagents HEC Hand Sanitizer Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00152282
Drug: Placebo and Premarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Study: NCT01494506
Drug: 5 Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks
Study: NCT01494506
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks
Study: NCT03456570
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets twice daily
Study: NCT01581970
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
Study: NCT02339584
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used as a placebo for masking purposes
Study: NCT03282643
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)
Study: NCT03838952
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
Study: NCT03101878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline .9%
Study: NCT02999178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04511273
Drug: Follow up of female sexual function
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50mg once daily for treatment of overactive bladder symptoms
Study: NCT01524653
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg po od
Study: NCT01524653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg po od
Study: NCT01458405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, blinded, intracoronary infusion of a placebo solution
Study: NCT00421005
Drug: fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
Study: NCT03703908
Drug: CCX140-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered tablet
Study: NCT04428203
Drug: Epidiolex Oral Liquid Product
Normalized name: Epidiolex Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Oral solution
Study: NCT04428203
Drug: Epidiolex Oral Liquid Product
Normalized name: Epidiolex Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral solution
Study: NCT00379756
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT00260481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
Study: NCT02857842
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00386009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken by mouth once a day for 12 weeks.
Study: NCT00585780
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical in appearance and dosing schedule as the active study medication was utilized
Study: NCT03977649
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo sc every 4 weeks
Study: NCT00769964
Drug: VA111913 TS / placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04366050
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02746796
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02746796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01946386
Drug: LEO 90100 Aerosol, foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
Study: NCT01946386
Drug: Daivobet® ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01946386
Drug: Dermovate® cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01946386
Drug: Synalar® ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02398747
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
Study: NCT01659307
Drug: Lactose powder
Normalized name: Lactose Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
Study: NCT02567838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Aquagel) was administered rectally prior to probe insertion.
Study: NCT01856309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
Study: NCT00944697
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oxycodone Naloxone tablets
Study: NCT01022047
Drug: Budecort Aqua
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
Study: NCT00005641
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005641
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005641
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00242866
Drug: GW274150
Approvals — FDA: no, EMA: no, PMDA: no
Description: The tablets used in this study will contain either 5mg or 30mg of GW274150
Study: NCT01433666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute intervention: single administration, capsulated form.
Study: NCT06059326
Drug: HSK7653 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, HSK7653 50 mg Q2W, 12 weeks
Study: NCT06059326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 0 mg Q2W, 12 weeks
Study: NCT02462330
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: injections of human albumin
Study: NCT04497831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation use
Study: NCT03937154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01878422
Drug: Arm B: FOLFIRI or FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX
Study: NCT01598701
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
Study: NCT01598701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL 0.9% Sodium Chloride
Study: NCT04512443
Drug: Daflon
Normalized name: Daflonex
Approvals — FDA: no, EMA: no, PMDA: no
Description: All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
Study: NCT02017964
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02017964
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00925769
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of 500/650/750/900mg/m2 bid
Study: NCT00074906
Drug: Venticute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
Study: NCT00604500
Drug: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
Study: NCT02223000
Drug: BIBV 308 SE solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04243850
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02223000
Drug: BIBV 308 SE capsule 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02223000
Drug: BIBV 308 SE capsule 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03263637
Drug: AZD4573
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4573 will be administered as a intravenous (IV) infusion.
Study: NCT00858156
Drug: BG9928
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 75 mg single dose
Study: NCT02512978
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
Study: NCT02183571
Drug: Merck Glucophage® high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part I: Treatment A
Study: NCT00484432
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin: 60mg/m² every 3 weeks, until cumulative dose of 550 mg/m²
Study: NCT02022852
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
Study: NCT02022852
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
Study: NCT01205711
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01205711
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01205711
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03596385
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: long-term maintenance beta-blocker therapy
Study: NCT00368550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 14-week treatment period
Study: NCT01509300
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg IV on day-3 and -2
Study: NCT04335578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo (PBO) at pre-specified time-points.
Study: NCT00354536
Drug: GSK716155 subcutaneous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: albiglutide subcutaneous injection
Study: NCT03613844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for DHA
Study: NCT00670241
Drug: LEO 80185 vehicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily application
Study: NCT03281577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-954 placebo-matching IV infusion.
Study: NCT04188873
Drug: Preparation Combination NRT and Standard Duration Combination NRT
Normalized name: bismuth preparations, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit
Study: NCT04188873
Drug: Standard Duration Combination NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks of nicotine patch + nicotine mini-lozenge
Study: NCT04188873
Drug: Extended Duration Combination NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks of nicotine patch + nicotine mini-lozenge
Study: NCT04056611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally.
Study: NCT02972840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT04092582
Drug: MTPS9579A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
Study: NCT04092582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
Study: NCT03210246
Drug: Microgynon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
Study: NCT03044171
Drug: In-office dental bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
Study: NCT03210246
Drug: Microgynon Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
Study: NCT04596631
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 52 weeks.
Study: NCT04062890
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo Pill
Study: NCT00193609
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
Study: NCT03956264
Drug: Kalinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gas mixture composed of 50% Nitrous Oxide and 50% Oxygen
Study: NCT00003172
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00690274
Drug: BF2.649
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 20mg per day
Study: NCT00690274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 20mg per day
Study: NCT00003172
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01748084
Drug: Placebo (NaCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
Study: NCT03982407
Drug: 68Ga-PSMA-11 PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
Study: NCT03205553
Drug: Peritoneal Dialysis Solution/Dextrose 1.5%
Normalized name: PERITONEAL DIALYSIS SOLUTION/DEXTROSE 1.5% SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial reductions will be performed with silastic silo placement for staged reduction with adjuvant direct peritoneal resuscitation (DPR). A JP drain will be securely placed through the top of the silo beneath the fascia at the base of the small bowel mesentery for instillation of dialysate fluid and aspiration of peritoneal fluid. The sterile syringe will then be connected to the JP drain. The dialysate fluid administered via JP drain as a bolus infusion every 6 hours until the abdominal wall is closed (generally 3-5 days), but not to exceed 7 days maximum. Fluid will be warmed at bedside using dry heat not to exceed 37°C/98°F. The initial bolus infusion will be 10 mL/kg of dialysate. If tolerated, each subsequent infusion will be increased by 10 mL/kg up to a goal infusion of 40 mL/kg (to a maximum volume of 100 mL) as tolerated. Dialysate will dwell for 1 hour after instillation of fluid. Any excess fluid will then be removed via JP drain.
Study: NCT01820026
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Second line therapy